NON-CONTRACEPTIVE PRODUCT AIMED AT STD PREVENTION WOULD WARRANT ACCELERATED NDA
This article was originally published in The Tan Sheet
NON-CONTRACEPTIVE PRODUCT AIMED AT STD PREVENTION WOULD WARRANT ACCELERATED NDA review because it would constitute "a very promising product" with "indications for which there [is] no satisfactory alternative," FDA Antiviral Drugs Division Director David Feigal, MD, said at an April 7 National Institutes of Health workshop. "If there was a [chemical] product that... specifically targeted HIV and allowed pregnancy, if there was preliminary data that suggested it was effective, then conceivably [such a product] might fall into [the] mechanisms" of accelerated approval by FDA, Feigal explained. He said that it was possible that the agency "could make these available to patients on a widespread basis while...waiting for the clinical trials to be completed," and suggested that randomized dose-response studies might be an appropriate Phase IV follow-up.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC